Lv4
500 积分 2025-09-09 加入
Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems
10天前
已完结
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
20天前
已完结
Pharmacological Inhibition of SLC33A1 Promotes Endoplasmic Reticulum Hyperoxidation and Induces Adaptive IRE1/XBP1s Signaling
26天前
已完结
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models
27天前
已完结
The long return on discovery science in cancer therapeutics
1个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
AKR1C1 Promotes ADC Resistance by Altering Uptake and Export
1个月前
已关闭
Endocytic evasion confers resistance to antibody-drug conjugates therapy in cancer
2个月前
已完结
AKR1C1 Promotes ADC Resistance by Altering Uptake and Export
2个月前
已关闭
AKR1C1 Promotes ADC Resistance by Altering Uptake and Export
2个月前
已关闭
皖公网安备34019202002308
